Gowda Charitha, Lo Re Vincent
Department of Pediatrics, The Ohio State College of Medicine, Columbus, OH, USA.
Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Curr Hepatol Rep. 2018 Jun;17(2):111-120. doi: 10.1007/s11901-018-0394-x. Epub 2018 Mar 24.
Direct-acting antiviral regimens for chronic hepatitis C virus (HCV) became available in 2014, and these highly curative therapies have the potential to reduce HCV-associated morbidity and mortality, decrease transmission, and eliminate HCV infection as a public health problem. This review summarizes the recommendations by the National Academies of Sciences, Engineering, and Medicine for a US strategy for HCV elimination.
To achieve proposed targets of reducing HCV incidence by 90% and decreasing HCV-related mortality by 60% by 2030, there is a critical need to improve HCV diagnosis and linkage to care; reduce HCV-related disease by antiviral treatment scale-up; reduce HCV incidence; and strengthen HCV surveillance to determine achievement of HCV elimination targets over time.
While HCV elimination is feasible, success of this national effort will require ongoing collaboration and critical resource investment by key stakeholders, including medical and public health communities, legislators, community organizers, and patient advocates.
2014年出现了用于慢性丙型肝炎病毒（HCV）感染的直接抗病毒治疗方案，这些高治愈率的疗法有潜力降低HCV相关的发病率和死亡率，减少传播，并消除HCV感染这一公共卫生问题。本综述总结了美国国家科学院、工程院和医学院关于美国消除HCV战略的建议。
为实现到2030年将HCV发病率降低90%以及将HCV相关死亡率降低60%的既定目标，迫切需要改善HCV诊断及与治疗的衔接；通过扩大抗病毒治疗减少HCV相关疾病；降低HCV发病率；并加强HCV监测以确定随着时间推移消除HCV目标的实现情况。
虽然消除HCV是可行的，但这项全国性工作的成功将需要关键利益相关者持续合作并进行重要资源投入，这些利益相关者包括医疗和公共卫生界、立法者、社区组织者以及患者权益倡导者。
